Hims & Hers Stock Plunges Despite 49% Revenue Surge
Hims & Hers Health Inc. (HIMS) reported a 49% revenue increase to $890.3M in Q3, but shares fell 12% due to slower subscriber growth and lowered profit expectations. Subscribers decreased by 100,000 to 2.8M, though up 13% year-over-year. The company reduced its full-year adjusted EBITDA and sales forecasts.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut drove a 12% share decline, highlighting immediate downside risk.
Market read
The new guidance and subscriber slowdown are material for traders; the stock's sharp intraday drop suggests actionable short‑term opportunities.
What to watch
International sales surged fourfold and the company is expanding into UK and Germany markets, which may offset near‑term subscriber declines.
Background
Hims & Hers reported Q3 results with strong revenue growth but weaker subscriber metrics and lowered guidance.
Ticker impact
Q3 results show 49% revenue rise but slower subscriber growth, lower profit outlook and guidance cut, causing a 12% share drop.
downward pressure as the market prices in weaker guidance and growth concerns
The company lowered full-year EBITDA and sales guidance, and subscriber base fell quarter-over-quarter, which typically triggers sell‑offs.
Market effects
Telehealth and digital health sector may see broader scrutiny as growth slows for a high‑profile player.
U.S. market sentiment likely dampened in health‑tech stocks.
Limited to U.S. listed health‑tech firms; no immediate global ripple.
Counterpoint
Weight‑loss drug partnerships could unlock new revenue streams, offering a longer‑term upside despite short‑term weakness.
Key entities
- companyHims & Hers Health Inc.
U.S. telehealth provider
